SARASOTA, Fla., Nov. 10, 2004 (PRIMEZONE) -- The following is an investment opinion issued by eLocity Inc.: Wellstone Filters (OTCBB:WLSF); Siebel Systems, Inc. (Nasdaq:SEBL); Neurocrine Biosciences, Inc. (Nasdaq:NBIX).
Investors, take a look at Wellstone Filters (OTCBB:WLSF), a company that develops and patents filter material that removes certain carcinogens and other toxins produced when tobacco is smoked, without removing the compounds thought to be associated with the pleasurable effects of smoking. The company announced Wednesday that, as a result of the issuance of its South American patents, it is preparing to market Wellstone cigarettes in South America, with emphasis on the large markets in Brazil and Argentina. Argentina has about 12 million adult smokers, or about 40% of the adult population, and Brazil 31 million adult smokers, or 31% of adults, according to the World Bank. Wellstone's strategy in South America is to exploit niche markets by employing its patented filter not only for discount lines but also for a premium brand. he entry into the South America market is part of Wellstone's goal to be the largest of the independent manufacturers.
The company was founded to develop filter technology which would, to the extent possible, remove harmful substances from tobacco smoke. Wellstone believes that its patented filter formulation removes tars and certain carcinogens, while providing better taste. Wellstone seeks to promote material for cigarette filters that will enable major cigarette manufacturers to provide consumers with an equally enjoyable cigarette with substantially fewer carcinogens.
WLSF is currently trading at around .65 cents a share.
Other Stocks in the News on Wednesday:
Siebel Systems, Inc. (Nasdaq:SEBL)
eBusiness applications company, Siebel Systems, Inc., announced Wednesday that Germany's T-Systems would deploy Siebel CRM OnDemand for about 1,000 sales staff around the world. Siebel said the hosted CRM implementation would be integrated with T-Systems' Siebel on premise solution in Germany.
Neurocrine Biosciences, Inc. (Nasdaq:NBIX)
Biopharmaceutical company, Neurocrine Biosciences, Inc., announced Wednesday that it has entered into a licensing agreement with Spanish pharmaceutical company Almirall Prodesfarma, S.A. for A2A receptor antagonists for Parkinson's Disease.
About eLocity Inc: eLocity owns and operates three financial websites for investors.
-- PennyPicks.com, http://www.pennypicks.com/. Featuring active message boards for the penny stock trader, rumors and more.
-- StockGrid.com, http://www.stockgrid.com/. Visit this site for our daily top stock "GRID Makers". We rank stocks on volume, message board activity, sentiment and trend forecast.
-- Bell2Bell.com, http://www.bell2bell.com/. Bell2Bell features news stories, rumors, the InvestBoard and more.
Sign up for FREE at any of the sites above.
The newsletter is provided by eLocity Inc., an electronic broadcaster and publisher of this newsletter, is here after referred to as "the company". The company received compensation for newsletter services for WLSF. (Public Company). The compensation is twelve-hundred dollars from a non-affiliated third party Media One. Because the company received compensation for its services, there is an inherent conflict of interest in the company statements and opinions and such statements and opinions cannot be considered independent.
The company reserves the right to trade in securities mentioned herein, and may make purchases or sales in such securities featured within our newsletter reports. The information contained in this publication is for informational purposes only, and not to be construed as an offer to sell or solicitation of an offer to buy any security. The company makes no representation or warranty relating to the validity of the facts presented nor does the company represent or warrant that all material facts necessary to make an investment decision are presented above. All statements of opinions, if any, (Our Summary) are those of the company.
The company relies exclusively on information gathered on the Public Company, such as public filings, press releases and its web sites. Investors should use the information contained in this publication as a starting point for conducting additional research on the Public Company in order to allow the investor to form his or her own opinion regarding the Public Company. Factual statements contained in this publication are made as of the date stated and they are subject to change without notice. The company is not a registered investment adviser, broker or a dealer.
Investing in the Public Company that this newsletter is providing service for should be reviewed is speculative and a high-risk and may result in the loss of some or all of any investment made in the client. This release may contain statements that constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended.
The words "may," "would," "will," "expect," "estimate," "anticipate," "believe," "intend," and similar expressions and variations thereof are intended to identify forward-looking statements.